Edition:
United States

Analyst Research

Report Title Price
Provider : Pechala's Reports
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co announces Japan approves Daklinza (daclatasvir) and Sunvepra (asunaprevir) Dual Regimen


Monday, 7 Jul 2014 07:00am EDT 

Bristol-Myers Squibb Co:Says Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza(daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ) and Sunvepra (asunaprevir), a NS3/4A protease inhibitor.Says providing new treatment that can lead to cure for many patients in Japan who have no treatment options.Says Daklinza+Sunvepra Dual Regimen is Japan's first all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. 

Company Quote

72.18
-0.08 -0.11%
29 Apr 2016